The district court denied Amgen’s motion to dismiss on February 10, 2023, concluding that Regeneron sufficiently alleged state and federal antitrust claims, such as “anticompetitive conduct under an ...
Regeneron Pharmaceuticals (REGN) has disclosed a new risk, in the Capital Markets category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results